A Patient‐Centric, Digital Multimodal Post‐Market Approval Continuous Monitoring of Drug Safety & Efficacy Platform for Blarcamesine
This post-market approval continuous monitoring platform may benefit all stakeholders, including patients, clinicians, regulators, service providers and payors. This modularly digital platform can be customized to fit also other post-market approval monitoring.
Authors
- Kun Jin (ORCID: https://orcid.org/0000-0002-8208-7052)
- Christopher U. Missling
- Nicolas Guizard (ORCID: https://orcid.org/0000-0003-2660-5123)
- Audrey Gabelle
- William R Chezem (ORCID: https://orcid.org/0000-0002-8939-758X)
- Olivier Courrèges
- Luca Villa
- Ayoub Gueddou
- Elizabeth Gordon
- Mathilde Borrot
- Timo Grimmer
- Juan Carlos Lopez‐Talavera
- Marwan N. Sabbagh
Institutions
- Barrow Neurological Institute (US)
- Enzo Life Sciences (United States) (US)
- Erdyn (France) (FR)
- Technical University of Munich (DE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_106459
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00